Latest AI and machine learning research in dementia for healthcare professionals.
Amyloid-{beta} (A{beta}) PET imaging is a core biomarker and is sufficient for the biological diagnosis of Alzheimer's disease (AD). Here, we aimed to identify biologically meaningful subgroups across the continuum of A{beta} accumulation using a data-driven deep learning approach, without imposing predefined thresholds for A{beta} negativity or positivity. We analyzed 3,110 of A{beta} PET scans f...
Von Economo neurons (VENs) are selectively lost in behavioural-variant frontotemporal dementia (bvFTD) and reduced in autism spectrum conditions (ASC), yet their computational role in social learning remains unexplained. We train a spiking neural network (the VENCircuit) embedding VEN-like projection neurons (K=40, 2% of total) in a recurrent pyramidal circuit across 50 matched random initialisati...
Speech-based analysis offers a scalable and non-invasive approach for detecting cognitive decline, yet progress has been constrained by the limited av...
The detection of Alzheimers disease (AD) is considered crucial, as timely intervention can improve patient outcomes. Electroencephalogram (EEG)-based ...
Tau protein aggregation in the brain is a hallmark of Alzheimer's disease (AD). Positron emission tomography (PET) is the only in vivo method to visua...
Understanding the pathogenesis of amyloid-{beta} pathology in Alzheimer's Disease (AD) proves to be a challenge. In this work, we expand upon the appl...
Sleep posture is known to be relevant to various sleep disorders, such as sleep apnea, but it is not often quantified in sleep monitoring systems. We ...
The systemic, metabolic, lifestyle factors have established associations with Alzheimer's Disease (AD) through epidemiologic and AD-specific biomarker...
Accurate multiclass segmentation of the Circle of Willis (CoW) is essential for neurovascular disease management but remains challenging due to comple...
Accurate prediction of conversion from Mild Cognitive Impairment (MCI) to Alzheimers Diseases (AD) is essential for early intervention, however, devel...
Anxiety is usually gauged by self-report, yet a single symptom level can reflect disparate neural circuitry. In Alzheimer's disease and related dement...
Patients with dementia typically exhibit cognitive impairment, which is routinely assessed using the Mini-Mental State Examination (MMSE). Concurrentl...
Background Outcome after stroke varies according to stroke subtype by location, but healthcare systems data studies do not include subtyping informati...
The most common cause of dementia is Alzheimer disease, a progressive neurodegenerative disorder affecting older adults that gradually impairs memory,...
Alzheimer's disease (AD) confirmation often relies on positron emission tomography (PET) or cerebrospinal fluid (CSF) analysis, which are costly and i...
The benefits of interventions targeting cognitive aging vary substantially across individuals, largely owing to heterogeneity in aging-related comorbi...
Alzheimer's disease (AD) progresses heterogeneously across individuals, motivating subject-specific synthesis of follow-up magnetic resonance imaging ...
Despite significant neurobiological and pathological overlaps, Alzheimer's (AD) and Parkinson's (PD)-the primary threats to healthy aging-are still ma...
Background Individual clinical cognitive assessments (CCA) for Alzheimer's disease (AD) provide broad disease stratification but are limited in sensit...
ABSTRACT Background: RNA editing is a post-transcriptional modification that alters the sequence of an RNA transcript. Two types of RNA editing were f...